Conference
Earn CE
Free Samples
Magazine
Subscribe
Videos
Solutions Lab
Macro/Op-Ed
Practice
Science & Tech
Money
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Dental Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vistagen Therapeutics Inc
(NQ:
VTGN
)
3.530
-0.060 (-1.67%)
Streaming Delayed Price
Updated: 10:19 AM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vistagen Therapeutics Inc
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Expands Portfolio with New European Patent for AV-101
April 06, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Why VistaGen Therapeutics Stock Is Trading Higher Today
April 06, 2023
VistaGen Therapeutics (NASDAQ: VTGN) shares are trading higher after the company announced it received a new European patent for AV-101.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
April 06, 2023
Via
Benzinga
Vistagen Receives New European Patent for AV-101
April 06, 2023
From
Vistagen
Via
Business Wire
VistaGen Therapeutics's Return On Capital Employed Insights
February 09, 2023
Via
Benzinga
VistaGen Shares Plunge Amid Uncertainty Around Its Anxiety Trial
February 08, 2023
Via
Benzinga
Social Anxiety Disorder Impacts Around 23.7M People In US, Vistagen Releases Details Around Nasal Spray Treatment Program For It
March 30, 2023
Via
Benzinga
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Receives Positive FDA Feedback Regarding Use of LSAS in Planned Phase 3 Study
March 30, 2023
Via
Investor Brand Network
Exposures
Product Safety
FDA Provides Positive Feedback to Vistagen Regarding Use of the Liebowitz Social Anxiety Scale (LSAS) as an Endpoint in Phase 3 Development of Fasedienol (PH94B) for Treatment of Social Anxiety Disorder
March 30, 2023
From
Vistagen
Via
Business Wire
Why VistaGen Therapeutics Shares Are Trading Higher Today
March 22, 2023
VistaGen Therapeutics (NASDAQ: VTGN) shares are trading higher on Wednesday after the company announced data from its Phase 3 open-label study evaluating safety and tolerability of fasedienol.
Via
Benzinga
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Positive Results from PH94B Phase 3 Study
March 22, 2023
Via
Investor Brand Network
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
March 22, 2023
Via
Benzinga
Vistagen Announces Positive Data in Fasedienol (PH94B) Phase 3 Open-Label Study in Adults with Social Anxiety Disorder
March 22, 2023
From
Vistagen
Via
Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Provides Update on Phase 1 Clinical Trial of Proprietary PH10
March 09, 2023
Via
Investor Brand Network
Vistagen Announces Completion of Last Patient, Last Visit in Phase 1 Clinical Trial of Itruvone (PH10), an Investigational Pherine Nasal Spray for Major Depressive Disorder
March 08, 2023
From
Vistagen
Via
Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Participate at Upcoming Health Care Conference
March 02, 2023
Via
Investor Brand Network
Vistagen to Present at Cowen 43rd Annual Health Care Conference
March 02, 2023
From
Vistagen
Via
Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Secures US Patent for PH80 Nasal Spray for Treatment of Migraine
March 01, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Vistagen Announces Issuance of U.S. Patent for PH80 Nasal Spray for Treatment of Migraine
March 01, 2023
From
Vistagen
Via
Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
February 14, 2023
It's time to start another day of trading with a breakdown of the biggest pre-market stock movers investors need to watch for Tuesday!
Via
InvestorPlace
Why Frequency Therapeutics Are Trading Lower By 82%? Here Are Other Stocks Moving In Monday's Mid-Day Session
February 13, 2023
Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares jumped 120.5% to $1.02 after jumping over 72% on Friday.
Via
Benzinga
Why Hempacco Are Trading Lower By 58%? Here Are Other Stocks Moving In Friday's Mid-Day Session
February 10, 2023
Gainers SeqLL Inc. (NASDAQ: SQL) shares jumped 120% to $1.85 after dropping around 39% on Thursday. SeqLL recently announced the establishment of a two-year Cooperative Research and Development...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
February 10, 2023
Via
Benzinga
Why Alteryx Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
February 10, 2023
Gainers
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
February 09, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
February 08, 2023
Via
Benzinga
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q3 2023 Financial Results, Corporate Update
February 08, 2023
Via
Investor Brand Network
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
February 08, 2023
Via
Benzinga
Why Sintx Technologies Shares Are Trading Lower By 38%; Here Are 20 Stocks Moving Premarket
February 08, 2023
Gainers PainReform Ltd. (NASDAQ: PRFX) shares rose 89.5% to $0.9475 in pre-market trading. PainReform reported receipt of extension to Aug. 7, 2023 to meet the Nasdaq's minimum bid price requirement.
Via
Benzinga
Vistagen Provides Corporate Update and Reports Fiscal 2023 Third Quarter Financial Results
February 07, 2023
From
Vistagen
Via
Business Wire
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.